- Home
- PMM vs PRQR Comparison
PMM vs PRQR Comparison
Compare PMM & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMM
- PRQR
- Stock Information
- Founded
- PMM 1989
- PRQR 2012
- Country
- PMM United States
- PRQR Netherlands
- Employees
- PMM N/A
- PRQR N/A
- Industry
- PMM Investment Managers
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- PMM Finance
- PRQR Health Care
- Exchange
- PMM Nasdaq
- PRQR Nasdaq
- Market Cap
- PMM 251.7M
- PRQR 232.8M
- IPO Year
- PMM N/A
- PRQR 2014
- Fundamental
- Price
- PMM $6.09
- PRQR $2.19
- Analyst Decision
- PMM
- PRQR Strong Buy
- Analyst Count
- PMM 0
- PRQR 8
- Target Price
- PMM N/A
- PRQR $8.88
- AVG Volume (30 Days)
- PMM 118.3K
- PRQR 347.9K
- Earning Date
- PMM 01-01-0001
- PRQR 11-06-2025
- Dividend Yield
- PMM 4.68%
- PRQR N/A
- EPS Growth
- PMM N/A
- PRQR N/A
- EPS
- PMM 0.23
- PRQR N/A
- Revenue
- PMM N/A
- PRQR $20,129,184.00
- Revenue This Year
- PMM N/A
- PRQR N/A
- Revenue Next Year
- PMM N/A
- PRQR N/A
- P/E Ratio
- PMM $26.52
- PRQR N/A
- Revenue Growth
- PMM N/A
- PRQR 8.65
- 52 Week Low
- PMM $5.00
- PRQR $1.07
- 52 Week High
- PMM $6.42
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- PMM 73.20
- PRQR 47.76
- Support Level
- PMM $5.80
- PRQR $2.21
- Resistance Level
- PMM $5.87
- PRQR $2.50
- Average True Range (ATR)
- PMM 0.05
- PRQR 0.14
- MACD
- PMM 0.03
- PRQR -0.01
- Stochastic Oscillator
- PMM 100.00
- PRQR 32.61
About PMM Putnam Managed Municipal Income Trust
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.